drugset / Trial / NCT00128063
Succinylated Human Serum Albumin (Suc-HSA) for HIV-1 Infection
Phase 1/2
Completed
6 enrolled
International Antiviral Therapy Evaluation Center
Prothya Biosolutions · collabUniversity Medical Center Groningen · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of the study is to evaluate the pharmacokinetic behavior of Suc-HSA after consecutive daily intravenous (i.v.) doses. The secondary objectives are to evaluate the safety and tolerability and the antiretroviral and immunological effects of consecutive daily i.v. doses of Suc-HSA.
Timeline
- Start
- 2005-08
- Primary completion
- —
- Completion
- 2006-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Succinylated Human Serum Albumin | Protein / enzyme biologic | 10 mg/kg | Intravenous |